Generic Name for HYCAMTIN
Topotecan (as HCl) 4mg/vial; pwd for IV infusion after reconstitution and dilution; contains mannitol; preservative-free.
Legal Classification:
Rx
Pharmacological Class for HYCAMTIN
Topoisomerase inhibitor.
Manufacturer of HYCAMTIN
GlaxoSmithKline Pharmaceuticals
|
Indications for HYCAMTIN
Metastatic carcinoma of the ovary after failure of initial or subsequent chemotherapy. Stage IV-B, recurrent or persistent carcinoma of the cervix in combination with cisplatin.
Other Indications for HYCAMTIN
Adult dose for HYCAMTIN
Confirm baseline neutrophils >1,500cells/mm3 and platelets >100,000cells/mm3 prior to 1st course of therapy. Give by IV infusion over 30 minutes. Ovarian cancer: 1.5mg/m2 daily for 5 consecutive days starting on Day 1 of a 21-day cycle. Cervical cancer: 0.75mg/m2 on Days 1, 2, and 3; followed by cisplatin. Dose adjustments, renal impairment: see literature.
Children's dosing for HYCAMTIN
Not recommended.
Contraindications for HYCAMTIN
Severe bone marrow depression. Pregnancy (Cat.D). Nursing mothers.
Warnings/Precautions for HYCAMTIN
Monitor peripheral blood cell counts during therapy; hold subsequent doses until neutrophils >1,000cells/mm3, platelets >100,000cells/mm3, and hemoglobin ≥9g/dL. History of interstitial lung disease, pulmonary fibrosis, lung cancer, thoracic exposure to radiation, use of pneumotoxic drugs and/or colony stimulating factors: increased risk of interstitial lung disease; monitor, discontinue if occurs. Moderate to severe renal impairment. Avoid extravasation. Elderly.
Interactions for HYCAMTIN
Myelosuppression potentiated with platinum agents. Neutropenia potentiated by G-CSF.
Adverse Reactions for HYCAMTIN
See literature. Neutropenia, leukopenia, thrombocytopenia, anemia, GI upset, anorexia, abdominal pain, stomatitis, headache, dyspnea, cough, pyrexia, alopecia, fatigue; infection, sepsis, interstitial lung disease, neutropenic colitis (may be fatal).
How is HYCAMTIN supplied?
Single-use vials—1, 5